Takhzyro® (lanadelumab-flyo) – Expanded indication
February 3, 2023 - The FDA approved Takeda’s Takhzyro (lanadelumab-flyo), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.
Download PDF
